Is There a Role for Dose Modification of TKI Therapy in CML?

ABSTRACT:

Purpose of review

For patients with chronic phase chronic myeloid leukemia (CP-CML), there is an increasing focus on personalization of therapy with dose modifications of tyrosine kinase inhibitors (TKIs) to reduce side effects and maintain efficacy. Dose reductions are also being considered in clinical trials prior to treatment-free remission (TFR) attempts.

Recent findings

Recent retrospective analyses of large clinical trials show that dose modification/reduction is safe. Efficacy is generally maintained and side effects are improved. Clinical trials such as DESTINY have demonstrated that dose reduction is safe for patients in deep molecular remission and may be considered prior to a TFR attempt. Dose modifications are widely used to prevent and manage the toxicities of T

SUBMITTER: Copland M 

PROVIDER: S-EPMC6647386 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature